Human Ferritin Platform and Its Optimized Structures to Enhance Anti-Cancer Immunity
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Bo-Ram | - |
dc.contributor.author | Lee, Hyo-Jung | - |
dc.contributor.author | Huh, June | - |
dc.contributor.author | Yoon, Chul Joo | - |
dc.contributor.author | Oh, Se Jin | - |
dc.contributor.author | Song, Kwon-Ho | - |
dc.contributor.author | Jeong, Sojin | - |
dc.contributor.author | Kim, Jungwon | - |
dc.contributor.author | Lee, Kyung-Mi | - |
dc.contributor.author | Shin, Beom Soo | - |
dc.contributor.author | Jeong, Ji Hoon | - |
dc.contributor.author | Kim, Tae Woo | - |
dc.contributor.author | Lee, Jeewon | - |
dc.date.accessioned | 2022-03-04T23:40:20Z | - |
dc.date.available | 2022-03-04T23:40:20Z | - |
dc.date.created | 2022-02-09 | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 2366-3987 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/137794 | - |
dc.description.abstract | Although anti-cancer vaccination and immune checkpoint (IC) therapy have emerged as potent cancer treatment modalities, their application remains limited to a subset of patients due to vaccine adjuvant toxicities and IC-blocking antibody-associated systemic immune adverse events. Here, an innovative platform is reported for adjuvant- and antibody-free cancer immunotherapy using human heavy chain ferritin (huHF)-derived optimally designed structures presenting multiple-copies of tumor-specific antigens (TSAs) or IC molecules (ICMs) on their surface. Through structure-guided molecular design, TSA-presenting huHFs for targeting TSAs at dendritic cells (DCs) are constructed with preservation of huHF-intrinsic affinity for transferrin receptors on DCs, and multi-copies of an ICM are also presented on huHF for blocking a cognate regulatory IC. The adjuvant-free co-administration of TSA- and ICM-presenting huHFs effectively elicits TSA-specific CD8+ T cell activation, strikingly suppresses both tumor growth and interleukin 17+ CD4+ T cell responses, and generates long-lasting protective immunity, indicating that this novel approach offers a promising breakthrough in cancer immunotherapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | TRANSFERRIN RECEPTOR | - |
dc.subject | THERAPEUTIC AGENTS | - |
dc.subject | GOLD NANOPARTICLES | - |
dc.subject | TARGETED DELIVERY | - |
dc.subject | DENDRITIC CELLS | - |
dc.subject | ADVERSE EVENTS | - |
dc.subject | PEPTIDE | - |
dc.subject | VACCINE | - |
dc.subject | BINDING | - |
dc.subject | PROTEIN | - |
dc.title | Human Ferritin Platform and Its Optimized Structures to Enhance Anti-Cancer Immunity | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Huh, June | - |
dc.contributor.affiliatedAuthor | Lee, Kyung-Mi | - |
dc.contributor.affiliatedAuthor | Kim, Tae Woo | - |
dc.contributor.affiliatedAuthor | Lee, Jeewon | - |
dc.identifier.doi | 10.1002/adtp.202000208 | - |
dc.identifier.scopusid | 2-s2.0-85102050888 | - |
dc.identifier.wosid | 000600492900001 | - |
dc.identifier.bibliographicCitation | ADVANCED THERAPEUTICS, v.4, no.2 | - |
dc.relation.isPartOf | ADVANCED THERAPEUTICS | - |
dc.citation.title | ADVANCED THERAPEUTICS | - |
dc.citation.volume | 4 | - |
dc.citation.number | 2 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ADVERSE EVENTS | - |
dc.subject.keywordPlus | BINDING | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | GOLD NANOPARTICLES | - |
dc.subject.keywordPlus | PEPTIDE | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | TARGETED DELIVERY | - |
dc.subject.keywordPlus | THERAPEUTIC AGENTS | - |
dc.subject.keywordPlus | TRANSFERRIN RECEPTOR | - |
dc.subject.keywordPlus | VACCINE | - |
dc.subject.keywordAuthor | anti-tumor immunity | - |
dc.subject.keywordAuthor | cancer immunotherapy | - |
dc.subject.keywordAuthor | human heavy chain ferritin | - |
dc.subject.keywordAuthor | molecular design | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.